healthcare professional for medical advice
case symptom
disable joint pain
influenza
red skin lesion
edema
feeling of discomfort
skin
datum
primary objective of the
hive like swell on the face
interim
cumulative duration of exposure
ulcer
congestive heart failure
month after discontinuation
nonfatal myocardial infarction
substantial reduction in prior activity level
case of severe arthralgia
modest trend towards higher risk
severe joint pain
runny nose
n rrb
history of macrovascular disease
tumor promoter for urinary bladder tumor
active comparator
review of pioglitazone
rash
significant difference between pioglitazone
fluid retention
cold sweat
upper respiratory tract infection pioglitazone
glyburide
nausea
standard of care
least event
body ache
weakness
recent acute coronary syndrome
anxiety
pit edema
blur vision
discontinuation of dpp
light color stool
foot
month
irregular heartbeat
sore throat
nonfatal hepatic failure
swell of the eyelid
health care professional
hive
acute coronary syndrome
hepatic enzyme elevation
red irritated eye
slurred speech
involve use of a different dpp
weight gain
side
known heart disease
upper
eyelid
constipation
weight
trend
vildagliptin
back
elevated serum alanine aminotransferase
angioedema
chf hospitalization
troubled breathing
inflammation of the joint
adjust hazard ratio
depression
more dipeptidyl peptidase
find weaker association
heart failure
diagnose case of bladder cancer
nightmare
sitagliptin
urticaria
case
greatest number of case
finger
medicine
extreme fatigue
back pain
tightness in the chest
body
stomach pain continue
percutaneous intervention
loosening of the skin
peel
leg
confusion
use
abdomen
bone fracture
seizure
change in vision
alogliptin pioglitazone
concomitant insulin use
stomach
cough
dizziness
manufacturer
all cause mortality
muscle ache
inhibitor
coronary artery bypass graft
least hospitalize congestive heart failure event
hypoglycemia
hospitalizationpioglitazone
swell of the face
respiratory tract infection
confidence interval
tongue
placebo
user
increase urge
indigestion
significant association between exposure
upper respiratory tract infection alogliptin
sex organ
radiate
positive rechallenge
macular edema
cv
alogliptin
hematocrit
eye
silent
chf
unusual tiredness
sneeze
history of a known history of heart disease
puffiness
pioglitazone in combination with a sulfonylurea
loss of voice
require hospitalization
pain in the stomach
insufficient datum
placebo in alogliptin
blister
loss of appetite
increase risk
pioglitazone
hr
pharyngitis
give placebo in addition
sore
dilated neck vein
release result
linagliptin
steven johnson syndrome
chill
fda
medical attention
october
swollen lymph gland
bloat
revascularization in the leg
purple center
myalgia
n
vomit
uln
yellow eye
dipeptidyl peptidase
headache
december
upper limit of normal
decrease hemoglobin
throat
stroke
hypertension
anaphylaxis
saxagliptin
darken urine
decrease urine output
cool pale skin
muscle pain
cardiac intervention
we fda
placebo standard care
irregular breathing
bladder cancer
acute pancreatitis
difficulty with swallow
diarrhea
high cardiovascular risk
sinusitis
pioglitazone use
lip
pain in the
increase duration
bullous pemphigoid
first occurrence
fever
pain
itch
arthralgiapioglitazone
general feeling of tiredness
lower abdomen
painful urination
blood in the urine
hand
increase in the risk of urinary bladder tumor
white spot in the mouth
disable
nasopharyngitis
upper respiratory tract infection
ear congestion
fast heartbeat
lower leg
major leg amputation above the ankle
fulminant hepatic failurepioglitazone
concomitant insulin
cpk
increase hunger
first event
face
shakiness
postmarket case of fatal
increase risk of bladder cancer
high cv risk
headache pioglitazone
pain alogliptin
chest pain
elevation in serum creatine phosphokinase